OCT 22, 2020 3:05 PM CEST

NGS for precision oncology in solid tumors: from research to clinical practice

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    BIOGRAPHY

Abstract

Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is rapidly increasing. For example, targets for therapeutic intervention have been found in over 50% lung adenocarcinoma and intra-hepatic cholangiocarcinoma. Therefore, diagnostic laboratories will face the problem to assess different types of genetic alterations (single nucleotide variants, indels, copy number variation and gene fusions) in multiple genes in order to allow the identification of the most active treatment for patients with metastatic cancer. Next generation sequencing (NGS) and in particular targeted sequencing allows sequencing dozen to hundred genes in a single analysis. The European Society of Medical Oncology (ESMO) recently released recommendations on the use of NGS for patients with metastatic solid tumors. According to ESMO recommendations, NGS is the preferred diagnostic approach to assess actionable genomic alterations ready for clinical practice in selected cancer types, including lung adenocarcinoma, prostate cancer and cholangiocarcinoma. However, the use of larger panels for comprehensive genomic profiling is suggested in academic centers. These recommendations for the first time provide a rationale for the use of NGS in the clinical practice. The increasing number of biomarkers and matched therapies that are being approved will likely lead to an extension of the recommendation to use NGS to other tumor types.

Learning Objectives:
1. To increase the knowledge on precision oncology for solid tumors.
2. To increase the knowledge on the utility of next generation sequencing for genomic profiling of solid tumors.


Show Resources
You May Also Like
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAY 19, 2022 8:00 AM PDT
MAY 19, 2022 8:00 AM PDT
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
MAR 29, 2022 9:00 AM PDT
C.E. CREDITS
MAR 29, 2022 9:00 AM PDT
Date: March 29, 2022 Time: 09:00am (PDT), 12:00pm (EDT), 17:00 (GMT) Advances in molecular and immunodiagnostics are enabling a personalized, high-precision approach to health in many clin...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 07, 2021 10:00 AM PST
C.E. CREDITS
DEC 07, 2021 10:00 AM PST
Date: December 07, 2021 Time: 10:00am (PST) The RNAscope™ technology allows high sensitivity and spatial resolution providing pivotal single-cell information to gain better insights in...
FEB 24, 2022 9:00 AM PST
C.E. CREDITS
FEB 24, 2022 9:00 AM PST
Date: February 24, 2021 Time: 9:00am (PST), 12:00pm (EST) Cytokine profiling is a valuable tool used in preclinical research for monitoring an immune response and cell signaling pathways dur...
Loading Comments...
Show Resources